MedTrace Logo

Timing of Meal and Caffeine Intake on Substrate Use and Exercise Efficiency

NCT04106752 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2019-09-27

No results posted yet for this study

Summary

During the past decades, considerable emphasis has been directed to analyzing the potential role of caffeine on substrate use and exercise performance. Research shows that caffeine ingestion prior to exercise has beneficial effects on submaximal exercise capacity and time trial protocols. This effect is mediated by an increase in plasma free fatty acids and intramuscular triglyceride utilization, preserving muscle and liver glycogen. Generally, a dose between 4 - 9 mg/kg body mass is administered to athletes in order to observe a positive or ergogenic effect. Caffeine ingestion (6 mg/kg) improved exercise performance in a long duration protocol (2 hours + \~ 30 min time trial) regardless of the administration time (1 hour before or during exercise). Lower doses of caffeine (\~ 1.5 mg/kg), when added to a carbohydrate solution increased exercise performance in a similar fashion. In rats, caffeine has been shown to have a biphasic action on postprandial glucose metabolism. When ingested before a meal, hepatic glycogenesis is blunted. Its ingestion during and after a meal allows glycogenesis to occur. Manipulating meal and caffeine timing before low intensity exercise, comparable to every-day life activities, is of great interest in assessing substrate use and muscular efficiency. it would be also interesting to see how this meal or caffeine timing manipulation influence the energetics of different phenotypes.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Caffeine

Provide caffeine supplements with or without meal before exercise

Sponsors & Collaborators

  • American University of Beirut Medical Center

    lead OTHER

Principal Investigators

  • Elie-Jacques Fares, PhD · American University of Beirut Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-05
Primary Completion
2019-06-30
Completion
2019-07-29

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04106752 on ClinicalTrials.gov